Triple Flag Precious Metals Makes Leadership Changes-July 2024-www.financetom.com

Triple Flag Precious Metals Makes Leadership Changes

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Triple Flag Precious Metals Makes Leadership Changes

Sep 27, 2024 8:05 PM

05:26 PM EDT, 09/26/2024 (MT Newswires) -- Triple Flag Precious Metals ( TFPM ) said Thursday it appointed Sheldon Vanderkooy as chief executive.

Vanderkooy succeeds Shaun Usmar, who is leaving the company effective Thursday.

The company also appointed Eban Bari as chief financial officer and James Dendle as chief operating officer, starting Thursday.

Price: 17.35, Change: -0.03, Percent Change: -0.17

Previous page： Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance Next page： Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance

Dec 5, 2024

07:45 AM EST, 12/05/2024 (MT Newswires) -- Patterson Companies ( PDCO ) reported fiscal Q2 adjusted earnings Thursday of $0.47 per diluted share, down from $0.50 a year earlier. A single analyst polled by FactSet expected $0.47. Net sales for the fiscal quarter ended Oct. 26 was $1.67 billion, up from $1.65 billion a year earlier. Analysts surveyed by FactSet...

Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults

Dec 5, 2024

07:47 AM EST, 12/05/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it has started a late-stage clinical trial to assess investigational oral antiviral COVID-19 medicines Lagevrio or molnupiravir for the treatment of adults with COVID-19 who are at high risk for disease progression. Lagevrio is being developed by Merck ( MRK ) in collaboration with Ridgeback Biotherapeutics....

CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend

Dec 5, 2024

07:50 AM EST, 12/05/2024 (MT Newswires) -- CME Group ( CME ) said Thursday its board approved an annual variable dividend totaling $2.10 billion as well as a share repurchase program of up to $3 billion of Class A common stock. The dividend amounts to $5.80 per share and is payable Jan. 16, 2025, to shareholders of record as of...

Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand

Dec 5, 2024

07:45 AM EST, 12/05/2024 (MT Newswires) -- Southwest Airlines ( LUV ) said in a regulatory filing Thursday that it increased its Q4 unit revenue growth forecast to a range of 5.5% to 7% from the previous range of 3.5% to 5.5%, citing better-than-expected leisure travel demand and revenue optimization efforts. The carrier said it now expects Q4 capacity to...